← All trials
NCT06577337
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 12, 2024
- Primary completion
- Dec 15, 2025
- Completion date
- Dec 15, 2025
- First posted
- Aug 29, 2024
- Last posted
- Nov 11, 2024
- Enrollment
- 54
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Merck KGaALead sponsor
- Merck KGaAOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.